Evidence map›Paper›PMID 34339032›Full record

ReviewAdvances in experimental medicine and biology2021

PAX8, an Emerging Player in Ovarian Cancer.

Priyanka Gokulnath, Amata Amy Soriano, Tiziana de Cristofaro, Tina Di Palma, Mariastella Zannini

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Priyanka GokulnathInstitute of Experimental Endocrinology and Oncology 'G. Salvatore' (IEOS) - CNR, National Research Council, Naples, Italy.
Amata Amy SorianoInstitute of Experimental Endocrinology and Oncology 'G. Salvatore' (IEOS) - CNR, National Research Council, Naples, Italy.
Tiziana de CristofaroInstitute of Experimental Endocrinology and Oncology 'G. Salvatore' (IEOS) - CNR, National Research Council, Naples, Italy.
Tina Di PalmaInstitute of Experimental Endocrinology and Oncology 'G. Salvatore' (IEOS) - CNR, National Research Council, Naples, Italy.
Mariastella ZanniniInstitute of Experimental Endocrinology and Oncology 'G. Salvatore' (IEOS) - CNR, National Research Council, Naples, Italy. s.zannini@ieos.cnr.it.
Institute for Experimental Endocrinology and Oncology · ITNational Research Council · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian Cancer is one of the most lethal and widespread gynecological malignancies. It is the seventh leading cause of all cancer deaths worldwide. High-Grade Serous Cancer (HGSC), the most commonly occurring subtype, alone contributes to 70% of all ovarian cancer deaths. This is mainly attributed to the complete lack of symptoms during the early stages of the disease and absence of an early diagnostic marker.PAX8 is emerging as an important histological marker for most of the epithelial ovarian cancers, as it is expressed in about 90% of malignant ovarian cancers, specifically in HGSC. PAX8 is a member of the Paired-Box gene family (PAX1-9) of transcription factors whose expression is tightly controlled temporally and spatially. The PAX genes are well known for their role in embryonic development and their expression continues to persist in some adult tissues. PAX8 is required for the normal development of Müllerian duct that includes Fallopian tube, uterus, cervix, and upper part of vagina. In adults, it is expressed in the Fallopian tube and uterine epithelium and not in the ovarian epithelium. Considering the recent studies that predict the events preceding the tumorigenesis of HGSC from the Fallopian tube, PAX8 appears to have an important role in the development of ovarian cancer.In this chapter, we review some of the published findings to highlight the significance of PAX8 as an important marker and an emerging player in the pathogenesis of ovarian cancer. We also discuss regarding the future perspectives of PAX8 wherein it could contribute to the betterment of ovarian cancer diagnosis and treatment.

Indexed as

Ovarian NeoplasmsAdultCarcinoma, Ovarian EpithelialFallopian TubesFemaleHumansNeoplasm GradingPAX8 Transcription FactorPAX8 protein, humanPAX8 Transcription FactorBiomarkersCancer tissuesMetastasisOvarian cancersPAX genesTranscription factors

Identifiers

PMID34339032
OpenAlexW3188925242

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.